July 24, 2013: BioKier, a privately held development-stage pharmaceutical company focused on the treatment of diabetes, announced today that it has closed on a funding commitment of $1.7 million from Broadview Ventures and the American Heart Association’s Science & Technology Accelerator Program. This is the first institutional venture capital investment for BioKier, which has previously received seed funding from individuals and a Small Business Research Loan from the North Carolina Biotechnology Center.

 

Press Release